ephedrine acetate | 408334-49-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ephedrine acetate
• 英文别名: O-acetyl ephedrine；Pseudoephedrin；[2-(methylamino)-1-phenylpropyl] acetate
• CAS: 408334-49-6
• 化学式: C₁₂H₁₇NO₂
• 分子量: 207.272
• InChiKey: WCDSTFHSWVDGPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  溴化氰 、 ephedrine acetate 以 乙醚 、 氯仿 为溶剂， 反应 1.0h， 生成 O-acetyl ephedrine cyanamide
  参考文献：
  名称：

  Malik, Abdul; Afza, Nighat; Siddiqui, Salimuzzaman, Zeitschrift fur Naturforschung, Teil B: Anorganische Chemie, Organische Chemie, 1982, vol. 37, # 4, p. 512 - 518

  摘要：

  DOI：

文献信息

• A Process for the Preparation of R-(-)-N, Alpha-Dimethylphenethylamine (Levmethamfetamine) or S-(+)-N, Alpha-Dimethylphenethylamine (Methamphetamine) from D-Ephendrine, or L-Ephedrine Respectively
  申请人：Gollapudy Subrahmanyam

  公开号：US20080293971A1

  公开（公告）日：2008-11-27

  A process for synthesis of R-(−)-N,α-Dimethylphenethylamine (Levmetamfetamine, formula I), or S-(+)-N,α-Dimethyl phenethylamine (Methamphetamine, formula II), from d-ephedrine of formula III or l-ephedrine formula IV, the process comprising the steps of (a) acylating the d- or l-ephedrine base of formula III or formula IV with an acylating agent to make a reaction mixture containing a N-acylated ephedrines of formula V or formula VI; (b) deoxygenation of N-acylated ephedrines to make the compound of the formula VII or Formula VIII by using Raney Nickel catalyst; and (c) acid hydrolysis of the above deoxygenated products to get the levmetamfetamine or methamphetamine.

  一种从d-麻黄碱（式III）或l-麻黄碱（式IV）合成R-（-）-N，α-二甲基苯乙胺（左旋甲基苯丙胺，式I）或S-（+）-N，α-二甲基苯乙胺（甲基苯丙胺，式II）的方法，该方法包括以下步骤：（a）用酰化剂酰化式III或式IV的d-或l-麻黄碱基，制备含有式V或式VI的N-酰化麻黄碱的反应混合物；（b）使用Raney镍催化剂脱氧N-酰化麻黄碱，制备式VII或式VIII的化合物；（c）对上述脱氧产物进行酸水解，得到左旋甲基苯丙胺或甲基苯丙胺。
• A PROCESS FOR THE PREPARATION OF R-(-)-N, ALPHA-DIMETHYLPHENETHYLAMINE (LEVMETAMFETAMINE) OR S-(+)-N, ALPHA-DIMETHYLPHENETHYLAMINE (METHAMPHETAMINE) FROM d-EPHEDRINE OR L-EPHEDRINE RESPECTIVELY
  申请人：Emmellen Biotech Pharmaceuticals Limited

  公开号：EP1828105A1

  公开（公告）日：2007-09-05
• ORAL BILAYER TABLETS COMPRISING ACETYLSALICYLIC ACID AND PSEUDOEPHEDRINE, METHODS OF PREPARING AND USING THEREOF
  申请人：Bayer HealthCare LLC

  公开号：US20220151936A1

  公开（公告）日：2022-05-19

  The present disclosure relates generally to bilayer tablets comprising a combination of two active pharmaceutical ingredients, and more specifically to bilayer tablets comprising acetylsalicylic acid, pseudoephedrine, and a dissolution aid. The bilayer tablets utilize a combination of granulated and non-granulated acetylsalicylic acid along with a unique distribution of sodium carbonate as a dissolution aid that provide acetylsalicylic acid and pseudoephedrine in a single dosage form having rapid dissolution and long-term storage stability (low degradation). The present disclosure also provides methods of preparing and of using the bilayer tablets.
• [EN] A PROCESS FOR THE PREPARATION OF R-(-)-N, a-DIMETHYLPHENETHYLAMINE (LEVMETAMFETAMINE) OR S-(+)-N, a-DIMETHYLPHENETHYLAMINE (METHAMPHETAMINE) FROM d-EPHEDRINE OR L-EPHEDRINE RESPECTIVELY<br/>[FR] PROCEDE POUR LA PREPARATION DE LA R-(-)-N-a-DIMETHYLPHENETHYLAMINE (LEVMETAMFETAMINE) OU DE LA S-(+)-N-a-DIMETHYLPHENETHYLAMINE (METHAMPHETAMINE), A PARTIR DE LA D-EPHEDRINE OU L-EPHEDRINE RESPECTIVEMENT
  申请人：EMMELLEN BIOTECH PHARMACEUTICA

  公开号：WO2006067794A1

  公开（公告）日：2006-06-29

  [EN] A process for synthesis of R-(-)-N, a -Dimethylphenethylamine (Levmetamfetamine, formula I), or S-(+)-N, a - Dimethyl phenethylamine (Methamphetamine, formula II ), from d-ephedrine of formula III or l-ephedrine formula IV, the process comprising the steps of (a) acylating the d- or l-ephedrine base of formula III or formula IV with an acylating agent to make a reaction mixture containing a N- acylated ephedrines of formula V or formula VI ; (b) deoxygenation of N-acylated ephedrines to make the compound of the formula VII or Formula VIII by using Raney Nickel catalyst ; and (c) acid hydrolysis of the above deoxygenated products to get the levmetamfetamine or methamphetamine.
  [FR] L'invention concerne un procédé destiné à la synthèse de la R-(-)-N-a-diméthylphénéthylamine (levmétamfétamine, formule I), ou de la S-(+)-N-a-diméthylphénéthylamine (méthamphétamine, formule II), à partir de la d-éphédrine de formule III ou de la l-éphédrine de formule IV, le procédé comprenant les étapes consistant à : (a) acyler la base d- ou l-éphédrine de formule III ou de formule IV avec un agent d'acylation pour donner un mélange réactionnel contenant des éphédrines N-acylées de formule V ou de formule VI ; (b) désoxygéner les éphédrines N-acylées pour donner le composé de formule VII ou de formule VIII en utilisant le catalyseur au nickel de Raney ; et (c) hydrolyser en milieu acide les produits désoxygénés susmentionnés pour obtenir la levmétamfétamine ou la méthamphétamine.
• [EN] ORAL BILAYER TABLETS COMPRISING ACETYLSALICYLIC ACID AND PSEUDOEPHEDRINE, METHODS OF PREPARING AND USING THEREOF<br/>[FR] COMPRIMÉS BICOUCHES ORAUX COMPRENANT DE L'ACIDE ACÉTYLSALICYLIQUE ET DE LA PSEUDOÉPHÉDRINE, LEURS MÉTHODES DE PRÉPARATION ET D'UTILISATION
  申请人：[en]BAYER HEALTHCARE LLC

  公开号：WO2022103620A1

  公开（公告）日：2022-05-19

  The present disclosure relates generally to bilayer tablets comprising a combination of two active pharmaceutical ingredients, and more specifically to bilayer tablets comprising acetylsalicylic acid, pseudoephedrine, and a dissolution aid. The bilayer tablets utilize a combination of granulated and non-granulated acetylsalicylic acid along with a unique distribution of sodium carbonate as a dissolution aid that provide acetylsalicylic acid and pseudoephedrine in a single dosage form having rapid dissolution and long-term storage stability (low degradation). The present disclosure also provides methods of preparing and of using the bilayer tablets.